2025/08/22 更新

写真a

ゴチョウ　トシオ
後町　俊夫
所属
医学部 放射線医学講座放射線治療学分野 助教
職名
助教
外部リンク

学位

  • 医学博士 （ 2020年9月   札幌医科大学 ）

研究分野

  • ライフサイエンス / 放射線科学  / 放射線腫瘍学

学歴

  • 札幌医科大学   医学部   大学院医学研究科

    2015年4月 - 2020年9月

    　 詳細を見る

    国名： 日本国

    researchmap

  • 札幌医科大学   医学部   医学科

    2004年4月 - 2010年3月

    　 詳細を見る

    国名： 日本国

    researchmap

経歴

  • 札幌医科大学   放射線医学講座   助教

    2022年9月 - 現在

    　 詳細を見る

    国名：日本国

    researchmap

  • KKR札幌医療センター   放射線科

    2019年4月 - 2022年8月

    　 詳細を見る

    国名：日本国

    researchmap

  • 札幌医科大学附属病院   放射線治療科   診療医、研究員

    2013年4月 - 2019年3月

    　 詳細を見る

    国名：日本国

    researchmap

  • 札幌医科大学附属病院   初期臨床研修医

    2011年4月 - 2012年3月

    　 詳細を見る

    国名：日本国

    researchmap

  • 帯広厚生病院   初期臨床研修医

    2011年4月 - 2012年3月

    　 詳細を見る

    国名：日本国

    researchmap

論文

  • Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients. 国際誌

    Shoh Mafune, Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Ryu Okuda, Masahiro Iwasaki, Motoki Matsuura, Terufumi Kubo, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

    Anticancer research   44 ( 7 )   3077 - 3086   2024年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND/AIM: This study evaluated the association between programmed cell death-ligand 1 (PD-L1) and prognosis in patients with cervical cancer treated with postoperative radiation and the impact of neoadjuvant chemotherapy (NAC) on this association. PATIENTS AND METHODS: Immunohistochemical analysis was performed on biopsy specimens from 42 patients who did not receive NAC and from paired samples before (biopsies) and after (resected tissues) chemotherapy from 46 patients who received NAC to determine the association of PD-L1 with radiotherapy outcomes. RESULTS: In the non-NAC group, patients with ≥10% PD-L1-expressing tumor cells prior to treatment had better recurrence-free survival (RFS) than those with <10% PD-L1-expressing tumor cells (p=0.001). In the NAC group, RFS was significantly lower (p=0.005) in the group with a ≥5% reduction of PD-L1 expression in tumor cells after chemotherapy than in those with <5% reduction. In multivariate analysis, only PD-L1 expression (non-NAC group) and the change in PD-L1 expression (NAC group) were associated with RFS. CONCLUSION: Low PD-L1 expression in a cervical tumor prior to treatment was identified as a risk factor for a poor outcome after postoperative radiotherapy. Furthermore, NAC induces an immunological shift that reduces PD-L1 levels in tumor cells, thereby negatively impacting treatment outcomes.

    DOI： 10.21873/anticanres.17121

    PubMed

    researchmap

  • Prediction of Treatment Response Based on Nutritional Status and Tumor Immunity in Oropharyngeal Cancer Patients Treated With Chemoradiotherapy. 国際誌

    Mio Kitagawa, Juno Kaguchi, Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Ryu Okuda, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

    Cancer diagnosis & prognosis   4 ( 6 )   789 - 796   2024年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND/AIM: Radiotherapy (RT) for advanced oropharyngeal cancer (OPC) is effective, especially when combined with chemotherapy (CRT). However, its success can vary depending on factors, such as tumor stage, HPV infection (p16 status), and the patient's nutritional and immune status. This study examined the controlling nutritional status (CONUT) score and tumor immunity as predictive factors for treatment outcomes in OPC, aiming to develop a personalized risk score. PATIENTS AND METHODS: A retrospective analysis was conducted on 84 patients with OPC treated with definitive RT or CRT, and survival outcomes were compared based on various factors, including BMI, CONUT score, CD8 expression, and HLA class II expression. RESULTS: We observed better overall survival (OS) rates in CD8-positive patients and those with higher HLA class II expression. The univariate analysis identified stage, p16 status, BMI, CONUT score, and CD8 expression as significantly associated with OS. In multivariate analysis, stage, BMI, and CONUT score remained significant predictors of OS. A risk scoring system was developed based on stage, p16 status, BMI, CONUT score, and CD8 expression. Patients were categorized into low-risk and high-risk groups, with significantly better survival in the low-risk group. CONCLUSION: A combined risk score incorporating clinical, nutritional, and immune factors can improve the prediction of treatment outcomes for OPC patients. This risk stratification may enable personalized treatment plans and improve ΟS rates.

    DOI： 10.21873/cdp.10397

    PubMed

    researchmap

  • Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response. 国際誌

    Tomokazu Hasegawa, Masanori Someya, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Ryuu Okuda, Juno Kaguchi, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

    In vivo (Athens, Greece)   38 ( 3 )   1470 - 1476   2024年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND/AIM: Automated measurement of immunostained samples can enable more convenient and objective prediction of treatment outcome from radiotherapy. We aimed to validate the performance of the QuPath image analysis software in immune cell markers detection by comparing QuPath cell counting results with those of physician manual cell counting. PATIENTS AND METHODS: CD8- and FoxP3-stained cervical, CD8-stained oropharyngeal, and Ku70-stained prostate cancer tumor sections were analyzed in 104 cervical, 92 oropharyngeal, and 58 prostate cancer patients undergoing radiotherapy at our Institution. RESULTS: QuPath and manual counts were highly correlated. When divided into two groups using ROC curves, the agreement between QuPath and manual counts was 89.4% for CD8 and 88.5% for FoxP3 in cervical cancer, 87.0% for CD8 in oropharyngeal cancer and 80.7% for Ku70 in prostate cancer. In cervical cancer, the high CD8 group based on QuPath counts had a better prognosis and the low CD8 group had a significantly worse prognosis [p=0.0003; 5-year overall survival (OS), 65.9% vs. 34.7%]. QuPath counts were more predictive than manual counts. Similar results were observed for FoxP3 in cervical cancer (p=0.002; 5-year OS, 62.1% vs. 33.6%) and CD8 in oropharyngeal cancer (p=0.013; 5-year OS, 80.2% vs. 47.2%). In prostate cancer, high Ku70 group had worse and low group significantly better outcome [p=0.007; 10-year progression-free survival (PFS), 56.0% vs. 93.8%]. CONCLUSION: QuPath showed a strong correlation with manual counting, confirming its utility and accuracy and potential applicability in clinical practice.

    DOI： 10.21873/invivo.13593

    PubMed

    researchmap

  • Prediction of late adverse events in pelvic cancer patients receiving definitive radiotherapy using radiation-induced gamma-H2AX foci assay. 国際誌

    Masanori Someya, Tomokazu Hasegawa, Asako J Nakamura, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Sho Mafune, Yutaro Ikeuchi, Hiroshi Tauchi, Koh-Ichi Sakata

    Journal of radiation research   64 ( 6 )   948 - 953   2023年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Radiation can induce DNA double-stranded breaks, which are typically detected by the fluorescence of phosphorylated histone H2AX. In this study, we examined the usefulness of the dynamics of radiation-induced gamma-H2AX foci of peripheral blood lymphocytes (PBLs), as a marker of DNA repair ability, in predicting late adverse events from radiotherapy. A total of 46 patients with cervical, vaginal and anal canal cancers treated with radical radiotherapy between 2014 and 2019 were included in this analysis. Concurrent chemotherapy was administered in 36 cases (78.3%). Peripheral blood was obtained before treatment, and then irradiated ex vivo with 1 Gy X-ray. The ratio of radiation-induced gamma-H2AX foci in PBLs measured at 30 min and at 4 h was defined as the foci decay ratio (FDR). With a median follow-up of 54 months, 9 patients (19.6%) were observed to have late genitourinary or gastrointestinal (GU/GI) toxicity. The FDR ranged from 0.51 to 0.74 (median 0.59), with a significantly higher incidence of Grade 1 or higher late adverse events in the FDR ≥ 0.59 group. In multivariate analysis, FDR ≥ 0.59 and hypertension also emerged as significant factors associated with the development of late toxicities. Overall, our results suggest that measurement of radiation-induced gamma-H2AX foci in PBLs may predict the risk of late GU/GI toxicities from chemoradiotherapy, which can enable tailoring the radiation dose to minimize adverse effects.

    DOI： 10.1093/jrr/rrad079

    PubMed

    researchmap

  • 放射線感受性の個人差に基づく次世代の放射線治療と放射線防護 腫瘍および正常組織の放射線感受性予測に基づいた個別化放射線治療の実践(Personalized radiotherapy based on the prediction of radiosensitivity of tumors and normal tissues)

    Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Kitagawa Mio, Gocho Toshio, Mafune Shoh, Sakata Koh-ichi

    日本放射線影響学会大会講演要旨集   66回   12 - 12   2023年11月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本放射線影響学会  

    医中誌

    researchmap

  • 化学放射線+免疫療法を行った3期NSCLCにおける、末梢血リンパ細胞のTCRレパトア解析

    染谷 正則, 長谷川 智一, 北川 未央, 土屋 高旭, 後町 俊夫, 眞船 翔, 金関 貴幸, 蒔田 芹奈, 鳥越 俊彦, 坂田 耕一

    日本癌治療学会学術集会抄録集   61回   O46 - 3   2023年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

    医中誌

    researchmap

  • Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.

    Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki, Koh-Ichi Sakata

    Medical molecular morphology   2023年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000-2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells (P = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 (P = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells (P = 0.009 and P = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.

    DOI： 10.1007/s00795-023-00367-8

    PubMed

    researchmap

  • Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.

    Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Medical molecular morphology   56 ( 1 )   38 - 45   2023年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Resistance of cervical cancer to radiotherapy with concurrent chemotherapy (CCRT) results in a poor prognosis. To identify new biomarkers for predicting the treatment response and prognosis, we explored exosomal microRNA (miRNA) expression signatures associated with the outcome of cervical cancer patients treated with CCRT. Exosomes were isolated from the plasma of 45 patients prior to CCRT during 2014-2020, and miRNA analysis was performed by next-generation sequencing. At a median follow-up of 38 months, 26 patients were recurrence free, 15 patients had died of the disease, and 4 patients received salvage chemotherapy due to distant metastasis. Of the 2522 miRNAs detected, 9 (miR-148a-5p, 1915-3p, 3960, 183-5p, 196b-5p, 200c-3p, 182-5p, 374a-5p, and 431-5p) showed differential expression between the recurrence-free and recurrence groups. Patients were divided into high- and low-risk groups according to the cutoff of the miRNAs-based risk score calculated from respective expression levels. The high-risk group had significantly worse disease-specific survival than the low-risk group (p < 0.001). In addition, miR-374a-5p and miR-431-5p expression showed a weak inverse correlation with tumor-infiltrating CD8+ and FOXP3+ T cells, suggesting a potential inhibitory effect on CCRT by suppressing tumor immunity. This miRNA signature could improve non-invasive monitoring and personalized treatment for cervical cancer.

    DOI： 10.1007/s00795-022-00338-5

    PubMed

    researchmap

  • 末梢血リンパ球TCRレパトア解析を用いたNSCLCの治療効果予測(Prediction of Treatment Response in NSCLC using Peripheral Blood Lymphocyte TCR Repertoire Analysis)

    Someya Masanori, Hasegawa Tomokazu, Kitagawa Mio, Tsuchiya Takaaki, Fukushima Yuki, Gocho Toshio, Mafune Shou, Kanaseki Takayuki, Tokita Serina, Sakata Koh-ichi

    日本医学放射線学会学術集会抄録集   82回   S173 - S173   2023年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer. 国際誌

    Masanori Someya, Serina Tokita, Takayuki Kanaseki, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yoh Kozuka, Shoh Mafune, Yutaro Ikeuchi, Mamoru Takahashi, Keigo Moniwa, Kazuhiko Matsuo, Tadashi Hasegawa, Toshihiko Torigoe, Koh-Ichi Sakata

    Cancer science   113 ( 12 )   4394 - 4400   2022年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation therapy has improved the overall survival of patients with NSCLC, the synergistic action mechanisms of CRT and immunotherapy on T cells remain unclear. In addition, there is a paucity of reliable biomarkers to predict clinical responses to therapy. In this study, we analyzed T-cell receptor (TCR) sequences in the peripheral blood of five patients with NSCLC. T-cell receptor analysis was undertaken before treatment, after CRT, and after PD-L1 blockade. Notably, we observed the expansion and alteration of the dominant T-cell clonotypes in all cases with a complete response. In contrast, neither expansion nor alteration of the TCR repertoire was observed in cases with progressive disease. T cell expansion was initiated after CRT and was further enhanced after PD-L1 blockade. Our findings suggest the systemic effect of CRT on circulating T cells in addition to the curative effect on limited tumor sites. Dynamic changes in circulating T-cell clonotypes could have a prognostic significance for combined CRT and PD-L1 blockade.

    DOI： 10.1111/cas.15566

    PubMed

    researchmap

  • Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.

    Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Japanese journal of radiology   40 ( 5 )   458 - 465   2022年5月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Human papillomavirus (HPV)-related cancer is one of the diseases entities for which the applications of radiotherapy have been increasing. Recently, the process of carcinogenesis from HPV infection and the mechanism of tumor immunity that develops during disease progression have been elucidated. In this review, we will describe the mechanism of tumor immunity and how chemoradiotherapy may overcome and improve the efficacy of tumor immunity. We will also discuss the usefulness of proteins involved with tumor immunity as a predictive marker of radiotherapy response, and present an overview of ongoing clinical trials of combinations of immune checkpoint inhibitors and radiotherapy to demonstrate the promising combination therapy that has been currently emerging.

    DOI： 10.1007/s11604-021-01231-4

    PubMed

    researchmap

  • Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.

    Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Masakazu Hori, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Yoshihisa Matsumoto, Koh-Ichi Sakata

    Medical molecular morphology   54 ( 3 )   245 - 252   2021年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    To supplement clinical decision-making in the management of cervical cancer, various prognostic factors, including tumor immune microenvironments, were examined in patients with cervical cancer treated with definitive chemoradiotherapy. We retrospectively analyzed the expression of CD8, FoxP3, HLA-1, PD-L1, and XRCC4 in 100 cases of cervical cancer. The observed tumor immune microenvironments were also classified into three types: inflamed, excluded, and cold type. Less FoxP3+ T cells and cold-type tumor were found to be poor prognostic factors in addition to non-SCC, large pre-treatment tumor volume, and three or less cycles of concurrent chemotherapy based on multivariate analysis. Cold-type tumors had significantly worse prognoses than the other two types, whereas inflamed- and excluded-type tumors showed similar 5-year disease-specific survival (P < 0.001; 0% vs. 60.3% vs. 72.3%). Radiotherapy could overcome the inhibitory immune microenvironment that occurs in excluded type. Individualized combination therapy adapted to pre-treatment tumor immunity may be necessary to improve radiotherapy outcomes in cervical cancer.

    DOI： 10.1007/s00795-021-00290-w

    PubMed

    researchmap

  • Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. 国際誌

    Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Yu Takada, Masakazu Hori, Katsutoshi Miura, Mio Kitagawa, Toshio Gocho, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Japanese journal of clinical oncology   50 ( 11 )   1290 - 1297   2020年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    OBJECTIVE: To evaluate proteins related to tumor immune response and treatment outcome from radiotherapy for uterine cervical cancer patients. METHODS: We performed a retrospective immunohistochemical staining of 81 patients with uterine cervical cancer who underwent definitive radiotherapy. We examined the expression of programmed death ligand 1, human leukocyte antigen class I, tumor-infiltrating CD8+, and forkhead box P3+ (FoxP3+) T cells in tumor tissues. RESULTS: In biopsy specimen, patients with a higher number of CD8+ T cells and FoxP3+ T cells had a better disease-specific survival than patients with a lower number of CD8+ T cells and FoxP3+ cells (P = 0.018 and P = 0.009). Multivariate analysis showed that equivalent dose in 2 Gy fractions (EQD2) of the minimum dose to 90% of the high-risk clinical target volume, FoxP3+ T cells and expression of human leukocyte antigen class I were significant prognostic factors. When the EQD2 is 70 Gy or more, a higher local control rate is obtained regardless of the number of CD8- or FoxP3-positive cells. When EQD2 is <70 Gy, the number of CD8-positive cells has a significant impact on treatment outcome: the recurrence rate (local recurrence rate + distant metastasis rate) was 46.2% in the group with a CD8 value of 230 or higher, whereas the recurrence rate was 75.7% in the group with a CD8 value of less than 230. CONCLUSION: The combination of CD8 or FoxP3 with EQD2 can be potentially useful to predict the treatment results of radiotherapy for cervical cancer, leading to individualized optimal selection of treatment for cervical cancer.

    DOI： 10.1093/jjco/hyaa149

    PubMed

    researchmap

  • Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. 国際誌

    Takaaki Tsuchiya, Masanori Someya, Yu Takada, Tomokazu Hasegawa, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Masakazu Hori, Kensei Nakata, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   196 ( 8 )   725 - 735   2020年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: To evaluate radiotherapy-induced changes in the expression of programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), and human leukocyte antigen class I (HLA-1) in patients with uterine cervical cancer, as well as infiltration of CD8+ and Forkhead box P3+ (FoxP3+) T lymphocytes into tumor tissue and the prognostic value of these parameters. MATERIALS AND METHODS: We performed immunohistochemical analysis of pre-radiotherapy biopsies and corresponding post-radiotherapy resected tissues in 104 uterine cervical cancer patients undergoing preoperative chemoradiotherapy or radiotherapy alone. We scored the expression of various proteins to distinguish positive from negative samples. RESULTS: PD-L1-expressing tumor cells (PD-L1 TC) increased significantly after chemoradiotherapy (p = 0.043). CD8+ T cell infiltration (p = 0.002) and FoxP3+ T cell infiltration (p = 0.003) decreased significantly after chemoradiotherapy. Expression of PD‑1, PD-L1-expressing immune cells (PD-L1 IC), and HLA‑1 did not change after chemoradiotherapy. In biopsy specimens obtained before chemoradiotherapy or radiotherapy, greater infiltration of CD8+ T cells (p = 0.001) and FoxP3+ T cells (p = 0.003) were significant predictors of better overall survival (OS). In surgical specimens obtained after chemoradiotherapy or radiotherapy, greater infiltration of PD-L1 TC was the only significant predictor of better OS (p < 0.001) and was related to a significantly lower probability of out-of-field recurrence (p = 0.005). CONCLUSION: Chemoradiotherapy induced an immunologic shift that increased PD-L1 TC. Chemoradiotherapy has immunological effects that can influence the results of treatment for uterine cervical cancer.

    DOI： 10.1007/s00066-019-01571-1

    PubMed

    researchmap

  • Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer. 国際誌

    Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Yuuki Fukushima, Masakazu Hori, Katsutoshi Miura, Yu Takada, Kensei Nakata, Koh-Ichi Sakata

    Journal of radiation research   61 ( 2 )   265 - 274   2020年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Combining external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT) is important for definitive treatment of cervical cancer. In cervical cancer patients receiving radiotherapy, we evaluated treatment outcomes in relation to dose-volume histogram parameters, including the computed tomography (CT)-based high-risk clinical target volume (HR-CTV) for ICBT. Between 2010 and 2015, 89 consecutive cervical cancer patients were mostly treated with 40 Gy of EBRT in 20 fractions and 18 Gy of ICBT prescribed to point A in 3 fractions. CT scans were obtained during ICBT. The HR-CTV D90 was calculated and the total doses of ICBT and EBRT were converted to the equivalent dose in 2 Gy fractions (EQD2). When the patients were divided into four groups according to EQD2 of the HR-CTV D90, the 3-year local recurrence-free survival rates were 95.2, 78.4, 52.7 and 42.9% for patients receiving >80 , 70-80 , 60-70 and <60 Gy, respectively. There was a significant negative correlation between EQD2 of the HR-CTV D90 and the HR-CTV volume at first ICBT (r = -0.713). Local recurrence was more frequent when the HR-CTV volume was ≥22 cc and EQD2 of the HR-CTV D90 was <70 Gy. Multivariate analysis showed that EQD2 of the HR-CTV D90 and concurrent chemotherapy (≥4 cycles) were significant determinants of overall survival. HR-CTV D90 was an important prognostic indicator for local recurrence. HR-CTV D90 >70 Gy is required for the better local control, especially in patients with a larger HR-CTV (≥22 cc at initial ICBT).

    DOI： 10.1093/jrr/rrz099

    PubMed

    researchmap

  • Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy. 国際誌

    Toshio Gocho, Masakazu Hori, Yuuki Fukushima, Masanori Someya, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Masato Hareyama, Masaru Takagi, Kohei Hashimoto, Naoya Masumori, Koh-Ichi Sakata

    Brachytherapy   19 ( 3 )   290 - 297   2020年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    PURPOSE: To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer. METHODS AND MATERIALS: The minimum urethral dose (UD10, 30, and 90) and the percent volume of the urethra receiving the prescription dose (V100, V150) were calculated from the postimplant dose-volume histograms of 182 patients. We then calculated various urethral biologically equivalent doses (uBEDs) using different values of the α/β ratio and tissue repair half-time (t1/2) and examined the correlations with GU toxicity. RESULTS: Common dosimetric quantifiers, such as UD90 (brachytherapy) + UD50 (external beam radiotherapy), showed no correlation with Grade ≥ 2 GU toxicity. There was a significant correlation between Grade ≥2 GU toxicity and uBED when the α/β value was 0.5 or 1 Gy and t1/2 was 0.5-2.5 h. An uBED (α/β = 1.0, t1/2 = 0.5) had the largest hazard ratio for GU toxicity, and it was also significantly correlated with Grade ≥ 2 GU toxicity according to multivariate analysis. CONCLUSIONS: We observed a significant correlation of uBED with GU toxicity when α/β was 0.5 or 1.0 Gy and t1/2 was 0.5-2.5 h. As the simple formula we used has not been verified in basic experiments, more data are needed to validate our results.

    DOI： 10.1016/j.brachy.2020.02.007

    PubMed

    researchmap

  • Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. 国際誌

    Yuki Fukushima, Masanori Someya, Kensei Nakata, Masakazu Hori, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Hikaru Ikeda, Yoshihiko Hirohashi, Toshihiko Torigoe, Shintaro Sugita, Tadashi Hasegawa, Tetsuo Himi, Koh-Ichi Sakata

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   129 ( 2 )   409 - 414   2018年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND AND PURPOSE: To investigate influences of proteins involved with tumor immunity on outcomes of radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC). MATERIAL AND METHODS: We performed immunohistochemical staining to examine expressions of p16 and proteins involved with tumor immunity in 92 OPSCC patients treated with radiotherapy. RESULTS: Patients with abundant infiltrating CD8-positive cells had the significantly better overall survival (OS) rate than patients with fewer CD8-positive cells (p = 0.026). Patients with higher PD-L1 expression in tumor cells (TC 1-3) had a better outcome than those with low PD-L1 expression in tumor cells (TC 0) for both OS (p = 0.019) and progression-free survival (PFS) rate (p = 0.032). Patients with high PD-L1 expression in infiltrating immune cells (IC 3) showed significantly better OS (p = 0.009) and PFS (p = 0.011) than those with low PD-L1 expression (IC 0-2). Patients with p16-negative and IC 3 showed similar OS to patients with p16-positive and IC 0-2. P16-positive tumors had a significantly higher CD8-positive cell infiltration and PD-L1 expression in tumor cells than p16-negative tumors. CONCLUSIONS: In addition to tumor p16 expression, PD-L1 expression in TC and IC can be useful for predicting the response of OPSCC to radiotherapy.

    DOI： 10.1016/j.radonc.2018.08.023

    PubMed

    researchmap

  • Prediction of acute gastrointestinal and genitourinary radiation toxicity in prostate cancer patients using lymphocyte microRNA. 国際誌

    Masanori Someya, Masakazu Hori, Toshio Gocho, Kensei Nakata, Takaaki Tsuchiya, Mio Kitagawa, Tomokazu Hasegawa, Yuuki Fukushima, Koh-Ichi Sakata

    Japanese journal of clinical oncology   48 ( 2 )   167 - 174   2018年2月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: To search for novel biomarkers that can predict acute radiation toxicity, we conducted microRNA expression analysis of peripheral blood lymphocytes (PBLs). METHODS: The discovery cohort was 69 patients with localized adenocarcinoma of the prostate who received intensity-modulated radiation therapy between October 2007 and October 2010. The validation cohort was 72 patients treated with low-dose-rate brachytherapy between May 2008 and March 2014. After13 microRNAs were selected by TaqMan® Array analysis in a preliminary experiment, expression of these microRNAs in all samples was analyzed by RT-PCR. RESULTS: In the discovery cohort, the average prostate volume, the rectal volume receiving 70 Gy, and expression of miR-410 and miR-221 were significant risk factors for Grade 1-2 gastrointestinal toxicity. Receiver operating characteristic analysis showed that the area under the curve (AUC) was 0.807. The maximum dose to the urinary bladder, prostate volume, pretreatment urinary function score, and miR-99a and miR-221 expression were risk factors for Grade 2 genitourinary toxicity. The corresponding AUC was 0.796. In the validation cohort, reproducibility of these markers was confirmed for gastrointestinal toxicity, but not for genitourinary toxicity. CONCLUSION: Combining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.

    DOI： 10.1093/jjco/hyx181

    PubMed

    researchmap

  • Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy.

    Masakazu Hori, Masanori Someya, Yoshihisa Matsumoto, Kensei Nakata, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yasushi Sato, Hiroyuki Ohnuma, Junji Kato, Shintaro Sugita, Tadashi Hasegawa, Koh-Ichi Sakata

    Medical molecular morphology   50 ( 1 )   25 - 33   2017年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    DNA double-strand break (DSB) is one of the most serious forms of damage induced by ionizing irradiation and is mainly repaired by the non-homologous end joining (NHEJ) repair. Immunohistochemical analysis of proteins involved in NHEJ, such as XRCC4 (X-ray repair cross-complementing protein 4), Ku86 and DNA-PKcs (DNA-dependent protein kinase, catalytic subunits), may be useful for predicting tumor radiosensitivity. We examined 92 patients with esophageal squamous cell carcinoma (ECSS) who were treated by radiotherapy between 1999 and 2008. Immunohistochemical examination of tumor tissue for Ki-67 and DSB-related proteins, including XRCC4, Ku86, and DNA-PKcs, was performed using pretreatment biopsy specimens. Low expression of XRCC4 was detected in 31 of 92 examined samples (33.7 %). The 5-year overall survival (OS) rate was 67.7 % in the low expression group and 31.0 % in the high expression group (P = 0.00). Multivariate analysis confirmed that advanced T-stage (HR 3.24, P = 0.01), radiation dose less than 66 Gy (HR 2.23, P = 0.02), absence of systemic chemotherapy (HR 2.59, P = 0.05), and high expression of XRCC4 (HR 12.0, P = 0.02) were independent prognostic factors for predicting poor OS. Other DSB-related proteins and Ki-67 were not predictive factors. XRCC4 expression might have an influence on results of radiotherapy for patients with ESCC.

    DOI： 10.1007/s00795-016-0144-5

    PubMed

    researchmap

▼全件表示

MISC

  • 当院において根治的放射線治療を行った食道癌症例の検討

    大黒敦矢, 眞船翔, 戸島有香, 芦名彩斗, 上山凌央, 後町俊夫, 土屋高旭, 北川未央, 長谷川智一, 染谷正則

    北海道医学雑誌   99 ( 2 )   2024年

    　詳細を見る

  • 動注化学放射線療法と外科手術を行った口腔癌の免疫組織学的評価

    染谷正則, 池内佑太郎, 眞船翔, 長谷川智一, 土屋高旭, 北川未央, 後町俊夫, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   21st   2024年

    　詳細を見る

  • 化学放射線療法+免疫療法を行った3期切除不能非小細胞肺癌における,末梢血リンパ細胞のTCRレパトア解析

    染谷正則, 長谷川智一, 北川未央, 土屋高旭, 眞船翔, 後町俊夫, 池内佑太郎, 金関貴幸, 鳥越俊彦, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   20th   2023年

    　詳細を見る

  • 血中エクソソームmiRNAを用いた子宮頸癌の治療効果予測

    染谷正則, 土屋高旭, 福島悠希, 池内佑太郎, 眞船翔, 小塚陽, 北川未央, 後町俊夫, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   19th   2022年

    　詳細を見る

  • 子宮頸癌根治照射症例におけるCD8の浸潤形式と予後との関連

    染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

    日本癌治療学会学術集会抄録集   59回   O37 - 7   2021年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：(一社)日本癌治療学会  

    医中誌

    researchmap

  • 根治放射線療を行った進行期子宮頸癌症例における腫瘍免疫と予後の関連

    染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 高田 優, 中田 健生, 堀 正和, 三浦 勝利, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

    日本癌治療学会学術集会抄録集   58回   O16 - 4   2020年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

    医中誌

    researchmap

  • 当院における中間～高リスク群前立腺癌に対する小線源および外部照射併用療法での治療経験

    後町 俊夫

    Japanese Journal of Radiology   36 ( Suppl. )   6 - 6   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 当院における肺癌に対する体幹部定位放射線治療の治療成績

    征矢野 崇, 松本 健一, 後町 俊夫, 福島 悠希, 土屋 高旭, 北川 未央, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   8 - 8   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 中咽頭癌の治療成績ならびにHPV感染と免疫染色の関連性

    福島 悠希, 染谷 正則, 中田 健生, 堀 正和, 北川 未央, 土屋 高旭, 長谷川 智一, 後町 俊夫, 松本 健一, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   10 - 10   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 子宮頸癌の放射線治療成績と末梢血リンパ球のDNA-PK活性の関係

    染谷 正則, 松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 長谷川 智一, 北川 未央, 堀 正和, 中田 健生, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   11 - 11   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 当院での子宮頸癌の根治的放射線治療成績 192-Ir HDR RALS導入後6年での解析

    松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 北川 未央, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一, 高田 優, 池田 光, 三浦 勝利

    Japanese Journal of Radiology   36 ( Suppl. )   6 - 6   2018年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 食道癌生検標本における抗PD-L1抗体の発現

    堀 正和, 染谷 正則, 中田 健生, 北川 未央, 土屋 高旭, 長谷川 智一, 福島 悠希, 後町 俊夫, 松本 健一, 坂田 耕一

    北海道医学雑誌   92 ( 2 )   115 - 115   2017年11月

    　詳細を見る

    記述言語：日本語   出版者・発行元：北海道医学会  

    医中誌

    researchmap

  • 前立腺癌放射線治療患者のリンパ球を用いた消化管および尿路の急性期有害事象予測

    染谷 正則, 堀 正和, 長谷川 智一, 中田 健生, 土屋 高旭, 北川 未央, 後町 俊夫, 福島 悠希, 舛森 直哉, 坂田 耕一

    日本癌治療学会学術集会抄録集   55回   O7 - 1   2017年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本癌治療学会  

    医中誌

    researchmap

  • 腹部動脈瘤に対するコイル塞栓術の成績 3次元並びにPGLAコイル・Fiberedコイルを用いた塞栓

    奥田 洋輝, 廣川 直樹, 宇佐見 陽子, 齋藤 正人, 福島 悠希, 後町 俊夫, 坂田 耕一, 小野寺 耕一

    IVR: Interventional Radiology   31 ( 2 )   175 - 175   2016年6月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

  • 初診時に肺転移を有した上咽頭癌の1例

    後町 俊夫

    Japanese Journal of Radiology   34 ( Suppl. )   11 - 11   2016年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • CRT後出血死に至った頸部食道癌の1例

    福島 悠希, 堀 正和, 中田 健生, 染谷 正則, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 松本 健一, 坂田 耕一

    Japanese Journal of Radiology   34 ( Suppl. )   11 - 11   2016年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • 頸部食道癌に対するIMRTの治療経験

    福島 悠希, 堀 正和, 染谷 正則, 中田 健生, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 坂田 耕一, 大沼 啓之, 佐藤 康史, 加藤 淳二

    北海道医学雑誌   90 ( 2 )   154 - 155   2015年11月

    　詳細を見る

    記述言語：日本語   出版者・発行元：北海道医学会  

    医中誌

    researchmap

  • 胆管癌肝転移の腫瘍内部に形成された膿瘍に対して経皮的ドレナージを施行した1例

    小野寺 耕一, 畠中 正光, 廣川 直樹, 宇佐見 陽子, 齋藤 正人, 福島 悠希, 後町 俊夫, 奥田 洋輝, 坂田 耕一

    IVR: Interventional Radiology   30 ( 3 )   274 - 274   2015年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

  • HDR-RALSにおいて、アプリケーターによる直腸線量変化の検討

    後町 俊夫

    Japanese Journal of Radiology   33 ( Suppl. )   6 - 6   2015年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本医学放射線学会  

    医中誌

    researchmap

  • PVEとTAEにて切除可能となった肝IPNBの1例

    齊藤 正人, 廣川 直樹, 宇佐見 陽子, 土屋 高旭, 後町 俊夫, 坂田 耕一

    IVR: Interventional Radiology   29 ( 4 )   429 - 429   2014年12月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

  • 子宮全摘術後の腟断端残存/再発腫瘍に対する腔内照射の治療成績

    中田 健生, 染谷 正則, 堀 正和, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 坂田 耕一

    臨床放射線   59 ( 10 )   1372 - 1378   2014年10月

    　詳細を見る

    記述言語：日本語   出版者・発行元：金原出版(株)  

    医中誌

    researchmap

  • 左側門脈圧亢進症による胃静脈瘤に対してIVR治療した1例

    廣川 直樹, 斉藤 正人, 宇佐見 陽子, 奥田 洋輝, 後町 俊夫, 坂田 耕一

    IVR: Interventional Radiology   29 ( Suppl. )   322 - 322   2014年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

  • 乳癌肝転移動注リザーバー留置症例における肝外肝動脈変異の検討

    宇佐見 陽子, 廣川 直樹, 齋藤 正人, 後町 俊夫, 福島 悠希, 奥田 弘樹, 坂田 耕一

    IVR: Interventional Radiology   29 ( Suppl. )   328 - 328   2014年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

  • 当院におけるDP-CAR(腹腔動脈幹合併切除兼尾側膵切除)術前の血流改変術

    齊藤 正人, 廣川 直樹, 宇佐見 陽子, 後町 俊夫, 奥田 洋輝, 坂田 耕一

    IVR: Interventional Radiology   29 ( Suppl. )   250 - 250   2014年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本インターベンショナルラジオロジー学会  

    医中誌

    researchmap

▼全件表示

共同研究・競争的資金等の研究課題

  • リキッドバイオプシーを用いた個別化放射線治療の実践

    研究課題/領域番号：21K07680  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    染谷 正則, 池内 佑太郎, 小塚 陽, 後町 俊夫

    　 詳細を見る

    配分額：4160000円 （ 直接経費：3200000円 、 間接経費：960000円 ）

    ＜目的＞治療効果向上と有害事象軽減を目指した「個別化放射線治療」を実践するために、局所進行悪性腫瘍に対し、末梢リンパ球や血中の腫瘍由来エクソソームに存在する、mRNAやmiRNAの発現パターンを調べ、放射線治療効果を予測する。またDNA修復能の指標として末梢リンパ球の放射線誘発ガンマH2AXフォーカスを測定する事で有害事象を予測する。これらの手法を用いて個々の患者毎の特性に合わせて線量分割や照射体積を調整する。
    ＜方法＞以下に示す方法で、末梢血リンパ細胞およびエクソソーム内のmRNA/miRNA発現パターンや末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス形成能を測定した。
    (A) 血漿中からのエクソソームの抽出とRNA分離・発現解析は、QIAGEN社のexoRNeasy plasma kitを用いた。バイオアナライザーを用いてRNA濃度と目的となる２０‐２５塩基配列程度のmiRNAが取れている事を確認した。QIAseq miRNA Library Kitを用いてRNA解析を行なった。これまで子宮頸がん36例からのエクソソーム抽出を行い、再発リスクとなる候補miRNAを抽出する。
    (B) 末梢血リンパ細胞の放射線誘発ガンマH2AXフォーカス計測は、ex vivoでX線を１Gy照射し、３０分後および４時間後にリンパ球を分離・固定を行い、スライドグラス上で蛍光免疫染色を行い、蛍光顕微鏡下にフォーカス数をカウントし、その変化率を計算してDNA修復能力を数値化する。

    researchmap

  • 個別化放射線治療に向けたリキッドバイオプシーの応用

    研究課題/領域番号：18K07760  2018年4月 - 2021年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    染谷 正則, 後町 俊夫, 池内 佑太郎

    　 詳細を見る

    配分額：4420000円 （ 直接経費：3400000円 、 間接経費：1020000円 ）

    「個別化放射線治療」を実現させるために、リキッドバイオプシーを用い、血漿中に存在する腫瘍由来のエクソソームを調べ、癌の放射線感受性予測に応用した。腹部～骨盤部に放射線治療を施行した子宮頸癌、直腸癌、肛門癌、膵癌など合計で150名の患者より血液を採取し、リンパ球のDNA-PK活性測定、放射線誘発ガンマH2AXフォーカス測定を行い、血漿中のエクソソーム由来マイクロRNA発現解析を行った。血漿中のエクソソーム由来マイクロRNAが放射線治療効果予測に有用である事と、リンパ球DNA-PK活性が放射線治療による晩期有害事象予測に有用である可能性を示した。

    researchmap

  • バイオマーカーを用いた腹部骨盤部放射線治療後の治療効果および有害事象予測

    研究課題/領域番号：15K10001  2015年4月 - 2018年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    染谷 正則, 長谷川 智一, 後町 俊夫, 松本 健一

    　 詳細を見る

    配分額：4810000円 （ 直接経費：3700000円 、 間接経費：1110000円 ）

    骨盤部放射線治療を行った患者個々の治療効果および急性期有害事象の予測を目的とし、当院で局所限局期前立腺癌で根治的放射線治療を行った患者群141例を対象に採血、リンパ球を分離し、DNA損傷修復に関わるとされるDNA依存性プロテインキナーゼ(DNA-PK)活性測定およびマイクロRNA-410, 221, 99aなどの発現解析を行なった。その結果として、リンパ球のDNA-PK活性が前立腺癌患者における生化学的再発の予測因子になる事と、miRNA-221と410の組み合わせで急性期消化管有害事象を高い精度で予測する事が可能である事を示した。

    researchmap